ViziLite^® Plus with TBlue⁶³⁰™ Oral Lesion Identification and Marking System

As an adjuvant to conventional oral examinations, ViziLite Plus is currently marketed using its chemiluminescent technology for the identification of oral abnormalities, especially those undetected during the conventional visual examination. ViziLite-identified lesions are then marked with TBlue⁶³⁰ to allow visualization of the abnormality under regular patient lighting. Clinical studies are currently underway to strengthen the Company’s data portfolio of efficacy and to identify and evaluate cytological components which may be responsive to both ViziLite's chemiluminescence and TBlue⁶³⁰.

ZTC^®

As a proprietary ingredient in ViziLite Plus with TBlue⁶³⁰™, the Company continues to expand its clinical portfolio by assessing ZTC with in-vitro studies using human and animal cancer cell lines. This approach will enable the Company to evaluate ZTC as a potential photosensitizer in the mitigation of disease progression. Outcomes of these studies will allow the Company to ascertain effectiveness prior to proceeding to animal trials with attainable results.